Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 19 | 2024 | 364 | 2.980 |
Why?
|
| Hydroxyurea | 2 | 2020 | 224 | 0.740 |
Why?
|
| Recombinases | 2 | 2024 | 39 | 0.420 |
Why?
|
| Erythrocyte Aging | 1 | 2011 | 11 | 0.380 |
Why?
|
| Trityl Compounds | 1 | 2011 | 3 | 0.380 |
Why?
|
| Antisickling Agents | 1 | 2011 | 17 | 0.380 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2024 | 139 | 0.370 |
Why?
|
| Hemolysis | 1 | 2011 | 125 | 0.360 |
Why?
|
| Acetamides | 1 | 2011 | 109 | 0.350 |
Why?
|
| Cytapheresis | 1 | 2009 | 1 | 0.350 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 231 | 0.310 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 207 | 0.300 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2007 | 39 | 0.290 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2024 | 90 | 0.280 |
Why?
|
| Brain Stem Neoplasms | 1 | 2007 | 100 | 0.270 |
Why?
|
| Glioma | 4 | 2007 | 1986 | 0.260 |
Why?
|
| Cerebral Infarction | 3 | 2014 | 73 | 0.260 |
Why?
|
| Anemia | 2 | 2022 | 725 | 0.260 |
Why?
|
| Hemoglobin, Sickle | 4 | 2021 | 24 | 0.250 |
Why?
|
| Child | 24 | 2024 | 30572 | 0.250 |
Why?
|
| Child, Preschool | 17 | 2024 | 17083 | 0.240 |
Why?
|
| Neonatal Screening | 2 | 2017 | 187 | 0.240 |
Why?
|
| Magnesium Sulfate | 1 | 2014 | 55 | 0.220 |
Why?
|
| Menorrhagia | 1 | 2024 | 76 | 0.220 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 149 | 0.210 |
Why?
|
| Blood Transfusion | 3 | 2021 | 580 | 0.210 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 273 | 0.200 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1257 | 0.190 |
Why?
|
| Angola | 2 | 2018 | 5 | 0.190 |
Why?
|
| Thrombocytosis | 1 | 2022 | 142 | 0.190 |
Why?
|
| Malaria | 1 | 2021 | 91 | 0.180 |
Why?
|
| Alleles | 2 | 2024 | 2598 | 0.180 |
Why?
|
| Adolescent | 18 | 2024 | 32698 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 367 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 2659 | 0.170 |
Why?
|
| HIV Infections | 2 | 2022 | 2155 | 0.170 |
Why?
|
| Pain | 4 | 2017 | 1701 | 0.170 |
Why?
|
| Iron | 1 | 2022 | 380 | 0.170 |
Why?
|
| Malnutrition | 1 | 2022 | 220 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 159 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 378 | 0.160 |
Why?
|
| Pediatrics | 2 | 2018 | 1196 | 0.150 |
Why?
|
| Incidental Findings | 1 | 2010 | 283 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 7923 | 0.150 |
Why?
|
| Hemoglobins | 2 | 2022 | 480 | 0.150 |
Why?
|
| Hematology | 1 | 2018 | 98 | 0.140 |
Why?
|
| Paper | 1 | 2017 | 13 | 0.140 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 255 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 871 | 0.140 |
Why?
|
| Blood Pressure | 2 | 2014 | 1555 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2010 | 411 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 1329 | 0.140 |
Why?
|
| Humans | 34 | 2024 | 270804 | 0.130 |
Why?
|
| Platelet Count | 2 | 2022 | 489 | 0.130 |
Why?
|
| Ikaros Transcription Factor | 1 | 2015 | 53 | 0.130 |
Why?
|
| Infant | 9 | 2024 | 14003 | 0.130 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 1467 | 0.120 |
Why?
|
| Magnesium | 1 | 2015 | 170 | 0.120 |
Why?
|
| Quality Improvement | 3 | 2024 | 912 | 0.120 |
Why?
|
| Patient Care | 2 | 2018 | 148 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 1061 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 682 | 0.110 |
Why?
|
| Body Height | 1 | 2014 | 233 | 0.110 |
Why?
|
| Algorithms | 1 | 2024 | 3908 | 0.110 |
Why?
|
| Male | 18 | 2024 | 128520 | 0.110 |
Why?
|
| Lamivudine | 2 | 2022 | 28 | 0.100 |
Why?
|
| Length of Stay | 3 | 2015 | 1998 | 0.100 |
Why?
|
| Female | 19 | 2024 | 148936 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8607 | 0.100 |
Why?
|
| Global Health | 1 | 2017 | 672 | 0.100 |
Why?
|
| beta-Thalassemia | 1 | 2011 | 36 | 0.100 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 14 | 0.090 |
Why?
|
| Acute Chest Syndrome | 1 | 2011 | 9 | 0.090 |
Why?
|
| Hematocrit | 1 | 2011 | 149 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 4396 | 0.090 |
Why?
|
| Body Weight | 1 | 2014 | 1282 | 0.090 |
Why?
|
| Quality of Life | 3 | 2017 | 4810 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2015 | 2575 | 0.080 |
Why?
|
| Retrospective Studies | 8 | 2024 | 39982 | 0.080 |
Why?
|
| Risk Factors | 6 | 2024 | 17867 | 0.080 |
Why?
|
| Chest Pain | 1 | 2009 | 173 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 1754 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 566 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 2395 | 0.070 |
Why?
|
| Young Adult | 6 | 2023 | 22255 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 1435 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2014 | 613 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1956 | 0.070 |
Why?
|
| Brain | 1 | 2010 | 4199 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2007 | 261 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2023 | 1233 | 0.070 |
Why?
|
| Syndrome | 1 | 2009 | 1409 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 343 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 585 | 0.070 |
Why?
|
| Prognosis | 4 | 2024 | 22533 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1445 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 15280 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3533 | 0.060 |
Why?
|
| beta-Globins | 1 | 2024 | 6 | 0.060 |
Why?
|
| Hospitals, Special | 1 | 2014 | 26 | 0.060 |
Why?
|
| Narcotics | 1 | 2014 | 126 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 364 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 3656 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2023 | 97 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 6234 | 0.050 |
Why?
|
| Hypotension | 1 | 2014 | 225 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 207 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 306 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 296 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 2903 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 644 | 0.050 |
Why?
|
| Point Mutation | 1 | 2024 | 785 | 0.050 |
Why?
|
| Neoplasms | 2 | 2014 | 15951 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 503 | 0.050 |
Why?
|
| Optic Nerve Glioma | 1 | 2001 | 28 | 0.050 |
Why?
|
| Informed Consent | 1 | 2014 | 415 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 453 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 506 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 392 | 0.040 |
Why?
|
| Adult | 6 | 2024 | 82073 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 476 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 29 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 4971 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 796 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 1127 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2010 | 747 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 111 | 0.040 |
Why?
|
| Disease Management | 1 | 2024 | 1092 | 0.040 |
Why?
|
| Death Certificates | 1 | 1998 | 15 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 1557 | 0.040 |
Why?
|
| Probability | 1 | 2010 | 886 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 212 | 0.040 |
Why?
|
| United States | 3 | 2023 | 15834 | 0.040 |
Why?
|
| Isoelectric Focusing | 1 | 2017 | 52 | 0.040 |
Why?
|
| Sulfites | 1 | 2017 | 45 | 0.040 |
Why?
|
| Saponins | 1 | 2017 | 48 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2017 | 85 | 0.040 |
Why?
|
| Solubility | 1 | 2017 | 247 | 0.030 |
Why?
|
| Canada | 1 | 1998 | 441 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2015 | 2855 | 0.030 |
Why?
|
| Sex Factors | 1 | 2001 | 2180 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 2170 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 2804 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2015 | 143 | 0.030 |
Why?
|
| Texas | 2 | 2007 | 6445 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 417 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 122 | 0.030 |
Why?
|
| Middle Aged | 5 | 2015 | 90569 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 397 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2014 | 101 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 156 | 0.030 |
Why?
|
| Intelligence | 1 | 2014 | 133 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 260 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 626 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 1064 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 420 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 312 | 0.030 |
Why?
|
| Patient Selection | 1 | 2010 | 2032 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 705 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 5157 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 908 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 3395 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 5050 | 0.030 |
Why?
|
| Aged | 3 | 2011 | 73640 | 0.020 |
Why?
|
| Allografts | 1 | 2014 | 687 | 0.020 |
Why?
|
| Mass Screening | 1 | 2010 | 1547 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2011 | 33859 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 102 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 966 | 0.020 |
Why?
|
| Incidence | 1 | 2001 | 5824 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 496 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 7274 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 2312 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 2478 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2010 | 232 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 313 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 574 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 908 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 6766 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 6193 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 347 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 1076 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4320 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2004 | 67 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 273 | 0.010 |
Why?
|
| Cytarabine | 1 | 2010 | 2015 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2004 | 105 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2010 | 3040 | 0.010 |
Why?
|
| Remission Induction | 1 | 2010 | 3658 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 1761 | 0.010 |
Why?
|
| SEER Program | 1 | 2007 | 1052 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 13422 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 4495 | 0.010 |
Why?
|
| Ependymoma | 1 | 2004 | 264 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2004 | 325 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3429 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 10268 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 3463 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 4470 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 3430 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12535 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 4249 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 5099 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 15922 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 5779 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 5332 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 12979 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 16751 | 0.000 |
Why?
|